U.S. Markets closed

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
33.50-0.57 (-1.67%)
At close: 4:01PM EDT

33.76 +0.26 (0.78%)
After hours: 6:23PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close34.07
Open33.98
Bid33.18 x 900
Ask33.50 x 900
Day's Range33.14 - 34.25
52 Week Range24.10 - 46.62
Volume26,137,722
Avg. Volume8,097,852
Market Cap47.927B
Beta (5Y Monthly)0.97
PE Ratio (TTM)11.86
EPS (TTM)2.83
Earnings DateOct 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.00
  • Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke
    PR Newswire

    Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke

    Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within a broad population of patients with non-valvular atrial fibrillation (NVAF), including those who are at low-to-moderate risk of bleeding from the use of anticoagulation. The device will be compared to treatment with non-vitamin K antagonist oral anticoagulants (NOACs), considered the leading contemporary drugs for stroke risk reduction in this population.

  • Benzinga

    What Does Boston Scientific's Debt Look Like?

    Over the past three months, shares of Boston Scientific (NYSE: BSX) fell by 9.13%. Before having a look at the importance of debt, let us look at how much debt Boston Scientific has.Boston Scientific's Debt Based on Boston Scientific's financial statement as of August 5, 2020, long-term debt is at $9.28 billion and current debt is at $254.00 million, amounting to $9.53 billion in total debt. Adjusted for $1.72 billion in cash-equivalents, the company's net debt is at $7.81 billion.Let's define some of the terms we used in the paragraph above. Current debt is the portion of a company's debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents include cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Boston Scientific's $30.82 billion in total assets, the debt-ratio is at 0.31. Generally speaking, a debt-ratio more than one means that a large portion of debt is funded by assets. As the debt-ratio increases, so the does the risk of defaulting on loans, if interest rates were to increase. Different industries have different thresholds of tolerance for debt-ratios. A debt ratio of 35% might be higher for one industry and average for another.Importance Of Debt Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.However, interest-payment obligations can have an adverse impact on the cash-flow of the company. Equity owners can keep excess profit, generated from the debt capital, when companies use the debt capital for its business operations.Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics - including debt-to-equity ratio. Click here to learn more.See more from Benzinga * Click here for options trades from Benzinga * What Does Boeing's Debt Look Like? * A Look Into Sony's Debt(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.